@misc{indiciae3bda471852e9,
  title = {Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.},
  author = {Vangeel, L. and De Jonghe, S. and Maes, P. and Slechten, B. and Raymenants, J. and Andre, E. and Neyts, J. and Jochmans, D.},
  year = {2021},
  doi = {10.1101/2021.12.27.474275},
  url = {https://www.biorxiv.org/content/10.1101/2021.12.27.474275v1},
  note = {Source identifier: 10.1101/2021.12.27.474275}
}